Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc is poised for significant revenue growth, particularly driven by its Signatera test in oncology, as evidenced by a robust quarter with a 54% year-over-year increase in MRD volumes. The company’s expansion of reimbursement coverage across additional cancer types is expected to enhance average selling prices and contribute positively to gross margins and operating cash flow. Furthermore, Natera's notable revenue beat of approximately $80 million in Q3 and a raised guidance for 2025 by $160 million signal strong financial momentum and an optimistic outlook for the company.

Bears say

Natera Inc faces significant challenges that could negatively impact its financial outlook, primarily due to expected margin erosion from reductions in in-network pricing as its total addressable market (TAM) expands to include average-risk patients. Additionally, any adverse events such as regulatory setbacks, reimbursement issues, or disappointing financial results could further depress the stock's performance. The company's dependency on compelling data and successful expansion plans, coupled with the inherent risks in emerging markets, raises concerns about its overall growth potential and market position.

Natera (NTRA) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 15 analysts, Natera (NTRA) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $249.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $249.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.